<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497637</url>
  </required_header>
  <id_info>
    <org_study_id>HRC045277</org_study_id>
    <nct_id>NCT03497637</nct_id>
  </id_info>
  <brief_title>Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses</brief_title>
  <acronym>LIPSIASTRATEGY</acronym>
  <official_title>Comparison of Non-Invasive Vessel Fractional Flow Reserve Calculated From Angiographic Images Versus Fractional Flow Reserve in Patients With Intermediate Coronary Artery Stenoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leipzig Heart Institute GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart Center Leipzig - University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leipzig Heart Institute GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled, multicenter, open-label study designed to&#xD;
      assess whether vFFR is non-inferior to FFR in assessment of intermediate coronary stenosis in&#xD;
      terms of the occurrence of MACE during 12 months after randomization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary angiography is insensitive to assess the physiologic significance of a coronary&#xD;
      stenosis. Therefore, clinical guidelines support the use of pressure-derived fractional flow&#xD;
      reserve (FFR) to assess the hemodynamic significance of coronary stenosis. Nevertheless, the&#xD;
      penetration of FFR in clinical routine continues to be limited by its requirement for&#xD;
      pharmacological vasodilation, prolonged procedure time and adverse systemic effects from&#xD;
      adenosine.&#xD;
&#xD;
      Vessel-FFR (vFFR) is a novel method for evaluating the functional significance of coronary&#xD;
      stenosis by calculation of the pressure drop in the vessel based on computation of two&#xD;
      angiographic projections. The vFFR values at each point along the vessel are color-coded and&#xD;
      superimposed on the 3D epicardial model and cut-off values of â‰¤0.80 identical to standard&#xD;
      invasive FFR apply.&#xD;
&#xD;
      These developments may translate towards more physiology guided intervention bearing the&#xD;
      potential to improve clinical outcomes in patients with stable CAD. The ability to derive FFR&#xD;
      values from routinely performed coronary angiograms, without the practical drawbacks that&#xD;
      limit invasive techniques, could have an important impact on daily clinical practice.&#xD;
&#xD;
      To date no randomized outcome-based clinical trial has compared an image-based FFR&#xD;
      methodology with standard invasive FFR in terms of subsequent clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Event (MACE) rate</measure>
    <time_frame>1 year</time_frame>
    <description>composite of cardiac death, non-fatal myocardial infarction or unplanned revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE during long-term follow-up</measure>
    <time_frame>2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each component of the primary endpoint assessed by structured telephone interview and verification by hospital reports</measure>
    <time_frame>1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat revascularization (PCI or CABG) assessed by structured telephone interview and verification by hospital reports in case of event</measure>
    <time_frame>1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-over rate from the one strategy to the other</measure>
    <time_frame>at intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of analyzable lesions in both treatment arms</measure>
    <time_frame>at intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1926</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenoses</condition>
  <arm_group>
    <arm_group_label>Pd/Pa guided Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFR guided therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>measurement of FFR</intervention_name>
    <description>use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses</description>
    <arm_group_label>FFR guided therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>measurement of Pd/Pa</intervention_name>
    <description>use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses</description>
    <arm_group_label>Pd/Pa guided Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Willing to participate and able to understand, read and sign the informed consent&#xD;
             document before the planned procedure&#xD;
&#xD;
          -  Eligible for coronary angiography and/or PCI&#xD;
&#xD;
          -  Coronary artery disease in one or more native major epicardial vessels or their&#xD;
             branches by coronary angiogram with visually assessed de novo coronary stenosis in&#xD;
             which the physiological severity of the lesion is in question (typically 40-80%&#xD;
             diameter stenosis).&#xD;
&#xD;
          -  Stable angina or acute coronary syndrome (non-culprit vessels only and outside of&#xD;
             primary intervention during acute STEMI or NSTE-ACS)&#xD;
&#xD;
          -  Participation in another interventional study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous CABG with patent grafts to the interrogated vessel&#xD;
&#xD;
          -  Tandem stenoses separated by more than 10 mm that require separate pressure guide wire&#xD;
             interrogation or PCI (not to be interrogated or treated as a single stenosis)&#xD;
&#xD;
          -  Total coronary occlusions&#xD;
&#xD;
          -  Hemodynamic instability (Killip class III-IV)&#xD;
&#xD;
          -  Heavily calcified or tortuous vessels&#xD;
&#xD;
          -  Terminal disease with life expectancy of less than 12 months&#xD;
&#xD;
          -  STEMI within 48 hours of procedure&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
&#xD;
          -  ACS patients with difficulty in assessing which the culprit lesion is&#xD;
&#xD;
          -  Significant contraindication to adenosine administration (e.g. Asthma bronchiale)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Leipzig - University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Thiele, MD</last_name>
    <phone>+49 341 865 1428</phone>
    <email>holger.thiele@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

